Naeem Asad

Dr. Naeem Asad


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
NANaeem Asad
Naeem Asad
MLMichael Lyons
Michael Lyons
SRShirley Muniz Machado Rodrigues
Shirley Muniz Machado Rodrigues
JBJustina Burns
Justina Burns
TRThomas Roper
Thomas Roper
LJLimei Jin
Limei Jin
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections. In this manuscript, we describe a new approach to synthesizing 7-bromo-4-chloro-1H-indazol-3-amine from inexpensive 2,6-dichlorobenzonitrile. This synthetic method utilizes a two-step sequence including regioselective bromination and heterocycle formation with hydrazine to give the desired product in an overall isolated yield of 38–45%. The new protocol has been successfully demonstrated on hundred-gram scales without the need for column chromatography purification. This new synthesis provides a potential economical route to the large-scale production of this heterocyclic fragment of Lenacapavir.

30 October 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
LJLimei Jin
Limei Jin
DGDaryl Guthrie
Daryl Guthrie
ASAnand Hari Shinde
Anand Hari Shinde
RVRamesh Vediyappan
Ramesh Vediyappan
ASAline Aparecida Nunes de Souza
Aline Aparecida Nunes de Souza
RLRyan Littich
Ryan Littich
This article presents a new three-step process for lenacapavir sodium, a first-in-class HIV capsid inhibitor developed by Gilead Sciences. Lenacapavir has received FDA approval for both treatment of multi-drug resistant HIV (Sunlenca®, 2022) and PrEP (Yeztugo®, 2025). Previous medicinal chemistry synthetic routes relied on separate Pd-catalyzed cou-plings and involved atropisomeric intermediates, resulting in low efficiency. Gilead’s 2024 four-step process improved scalability but retained discrete Pd-catalyzed steps and early-stage incorporation of the costly chiral pyrazole carboxylic acid (Frag C). Our streamlined approach begins with a chiral bromopyridine (Frag A) and features a telescoped Heck-Suzuki coupling and late-stage amidation with Frag C. This marks the first reported one-pot Heck-Suzuki sequence in the synthesis of lenacapavir, minimizing atropisomer handling and simplifying Pd sequestration. The process yields lenaca-pavir API in 50–55% overall yield, with >99.9 wt% purity, and Pd content below 4.2 ppm.